Fourth Pfizer Dose Is Insufficient to Ward Off Omicron, Israeli Trial Suggests

Do you work on the project on the project repository? You can use this tool to automatically sync your releases to SourceForge, so that you can take advantage of SourceForge's massive reach, and you can keep using GitHub.

The story was 157796151.

BeauHD posted on Monday January 17, 2022, from the better-than-nothing dept.

Preliminary data from a trial in Israel shows that a fourth dose of the Pfizer-BioNTech vaccine was insufficient to prevent infections with the omicron variant of Covid-19. Two weeks after the start of the trial of 154 medical personnel at the Sheba Medical Center in Tel Aviv, researchers found the vaccine successfully raised antibody levels. Gili Regev-Yochay, the trial's lead researcher, said that that only offered a partial defense. She said that vaccines which were more effective against previous versions offer less protection. The people who were in the trial had only slight symptoms.

The fourth dose of the vaccine was rolled out to the over-60s in Israel in late December. More than half a million Israelis have received the extra dose, according to the Health Ministry. The decision to give the fourth vaccine to the most vulnerable was the correct one, since it may have given additional benefit against omicron. She said the results didn't support a wider roll out.



Even the most complex IT environments can be monitored and managed. So little time. It can be hard to keep a close eye on your clients when you are low on resources. The headaches get worse when tickets come in. The noise can be cut through with ConnectWise. With intelligent alerting, a fully staffed NOC, and advanced RMM tools, you can keep an eye on what's happening across networks to bring real-time results to your TSP.

A free demo is available.